Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

This study has suspended participant recruitment.
Sponsor:
Collaborator:
Information provided by:
University of Virginia
ClinicalTrials.gov Identifier:
NCT00278122
First received: January 16, 2006
Last updated: December 9, 2013
Last verified: December 2013
  Purpose

RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop tumor cells from growing. Giving paclitaxel together with GM-CSF may be effective in treating melanoma.

PURPOSE: This phase II trial is studying how well giving paclitaxel together with GM-CSF works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery.


Condition Intervention Phase
Melanoma (Skin)
Biological: sargramostim
Drug: paclitaxel
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: Evaluation of the Clinical Efficacy of Leukine® Administered in Conjunction With Paclitaxel in Patients With Advanced Melanoma

Resource links provided by NLM:


Further study details as provided by University of Virginia:

Primary Outcome Measures:
  • Clinical response by CT scans every 6 weeks [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Duration of response by CT scans every 6 weeks [ Designated as safety issue: No ]
  • Time to progression by CT scans every 6 weeks [ Designated as safety issue: No ]
  • Survival [ Designated as safety issue: No ]

Estimated Enrollment: 42
Study Start Date: July 2005
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

Primary

  • Assess the activity of paclitaxel and sargramostim (GM-CSF), in terms of objective clinical response rate (complete response [CR] and partial response [PR]), in patients with advanced unresectable melanoma.

Secondary

  • Evaluate the duration of response, time to progression, and overall survival of patients treated with this regimen.
  • Determine serum cytokine levels (GM-CSF, IFN-γ, aldesleukin, recombinant interleukin-4, and IL-10) in these patients.

OUTLINE: This is an open-label study.

Patients receive paclitaxel IV over 3 hours on day 1 and sargramostim (GM-CSF) subcutaneously on days 4-17. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete response (CR) receive 2 additional courses of therapy beyond CR for up to 12 courses.

After study treatment, patients are followed every 3-6 months for at least 3 years.

PROJECTED ACCRUAL: A total of 42 patients will accrued for this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed unresectable stage III or IV melanoma from a cutaneous, mucosal, or unknown primary site

    • Unresectable stage III disease, defined as meeting 1 of the following criteria:

      • Regional metastasis that, in the judgement of the treating physician, cannot be surgically resected with clear margins
      • Regional metastasis that can be surgically resected with clear margins only by extensive surgery that is inadvisable or unacceptable to the treating physician and/or patient
    • Staging of cutaneous and mucosal melanoma based on the revised American Joint Committee on Cancer (AJCC) staging system
  • Must have measurable disease as defined by Response Evaluation Criteria in Small Tumors (RECIST) criteria
  • No ocular melanoma
  • Patients with brain metastases may be eligible if all of the following are true:

    • Total number of brain metastases ever is ≤ 3
    • Each brain metastasis has been completely removed by surgery or each unresected brain metastasis has been treated with stereotactic radiosurgery

      • Stereotactic radiosurgery, such as gamma knife, can be used up to 1 week before study entry
      • No evident growth of any brain metastasis since treatment
    • No brain metastasis that is > 2 cm in diameter at study entry

PATIENT CHARACTERISTICS:

  • ECOG performance status 0-1
  • Absolute neutrophil count > 1,500/mm^3
  • Platelet count > 100,000/mm^3
  • Hemoglobin > 9 g/dL
  • AST and ALT ≤ 2.5 times upper limit of normal (ULN)
  • Alkaline phosphatase ≤ 2.5 times ULN
  • Bilirubin normal
  • Creatinine ≤ 1.5 times ULN
  • No New York Heart Association class III or IV heart disease
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No previous or concurrent autoimmune disorder requiring cytotoxic or immunosuppressive therapy
  • No autoimmune disorder with visceral involvement

    • The following conditions are allowed:

      • Laboratory evidence of autoimmune disease (e.g., positive ANA titer) without symptoms
      • Clinical evidence of vitiligo
      • Other forms of depigmenting illness
      • Mild arthritis requiring steroidal anti-inflammatory drugs
  • HIV negative
  • Hepatitis C negative
  • No other serious or poorly controlled medical condition that could be exacerbated by or complicate compliance with study therapy

PRIOR CONCURRENT THERAPY:

  • No more than 1 previous chemotherapy regimen for metastatic melanoma
  • No previous paclitaxel
  • No chemotherapy, interferon, growth factors, interleukin, or radiotherapy (excluding gamma knife therapy for brain metastases) within the past 4 weeks
  • No surgical resection of metastatic lesions within the past 4 weeks
  • No other investigational medication within the past 4 weeks or during study
  • No nitrosoureas (e.g., carmustine or lomustine) within the past 6 weeks and during study treatment
  • No other concurrent chemotherapy, interferon, other growth factors, interleukin, illegal drugs, radiotherapy, surgery, or steroid therapy
  • No concurrent oral or injectable hydrocortisone (at doses > 15 mg per day) or its equivalent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00278122

Locations
United States, Virginia
University of Virginia Cancer Center
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
University of Virginia
Investigators
Principal Investigator: William W. Grosh, MD University of Virginia
  More Information

Additional Information:
No publications provided

Responsible Party: William W. Grosh, University of Virginia Cancer Center
ClinicalTrials.gov Identifier: NCT00278122     History of Changes
Other Study ID Numbers: 11782, UVACC-MEL-46, UVACC-HIT-028.8, UVACC-PRC-350-04
Study First Received: January 16, 2006
Last Updated: December 9, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Virginia:
stage III melanoma
stage IV melanoma
recurrent melanoma

Additional relevant MeSH terms:
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 28, 2014